Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded ...

Recent upgrades from BofA Securities and KeyBanc have put fresh attention on Schrödinger (SDGR), as the company moves away ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

Total Revenue (Q4 2024): $88.3 million, a 19% increase compared to Q4 2023. Software Revenue (Q4 2024): $79.7 million, a 16% increase compared to Q4 2023. Drug Discovery Revenue (Q4 2024): $8.7 ...

Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...

Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Mr. Aklian joins Schrödinger from Certara, where he served as senior vice president, global software sales. In this role, Mr. Aklian led a global team of professionals in sales and operations and ...